KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) EBIT: 2009-2024

Historic EBIT for Pacira BioSciences (PCRX) over the last 16 years, with Dec 2024 value amounting to -$73.4 million.

  • Pacira BioSciences' EBIT rose 104.56% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.6 million, marking a year-over-year increase of 164.02%. This contributed to the annual value of -$73.4 million for FY2024, which is 183.69% down from last year.
  • Pacira BioSciences' EBIT amounted to -$73.4 million in FY2024, which was down 183.69% from $87.7 million recorded in FY2023.
  • Pacira BioSciences' EBIT's 5-year high stood at $89.9 million during FY2021, with a 5-year trough of -$73.4 million in FY2024.
  • For the 3-year period, Pacira BioSciences' EBIT averaged around $24.8 million, with its median value being $60.0 million (2022).
  • Its EBIT has fluctuated over the past 5 years, first skyrocketed by 342.27% in 2020, then crashed by 183.69% in 2024.
  • Pacira BioSciences' EBIT (Yearly) stood at $46.4 million in 2020, then soared by 94.01% to $89.9 million in 2021, then tumbled by 33.25% to $60.0 million in 2022, then spiked by 46.07% to $87.7 million in 2023, then tumbled by 183.69% to -$73.4 million in 2024.